FR2986538B1 - Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives - Google Patents

Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives

Info

Publication number
FR2986538B1
FR2986538B1 FR1251089A FR1251089A FR2986538B1 FR 2986538 B1 FR2986538 B1 FR 2986538B1 FR 1251089 A FR1251089 A FR 1251089A FR 1251089 A FR1251089 A FR 1251089A FR 2986538 B1 FR2986538 B1 FR 2986538B1
Authority
FR
France
Prior art keywords
mir
prognosis
targets
diagnosis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1251089A
Other languages
English (en)
Other versions
FR2986538A1 (fr
Inventor
Nicolas Pottier
Bernard Mari
Brice Marcet
Pascal Barbry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Lille CHU
Original Assignee
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Regional Universitaire de Lille CHRU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1251089A priority Critical patent/FR2986538B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Regional Universitaire de Lille CHRU filed Critical Centre National de la Recherche Scientifique CNRS
Priority to ES13712915.1T priority patent/ES2642188T3/es
Priority to EP13712915.1A priority patent/EP2812449B1/fr
Priority to JP2014556174A priority patent/JP6193269B2/ja
Priority to US14/376,569 priority patent/US20150045247A1/en
Priority to CA2862275A priority patent/CA2862275C/fr
Priority to DK13712915.1T priority patent/DK2812449T3/en
Priority to PCT/IB2013/050989 priority patent/WO2013118066A1/fr
Publication of FR2986538A1 publication Critical patent/FR2986538A1/fr
Application granted granted Critical
Publication of FR2986538B1 publication Critical patent/FR2986538B1/fr
Priority to US15/397,351 priority patent/US10647984B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
FR1251089A 2012-02-06 2012-02-06 Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives Active FR2986538B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR1251089A FR2986538B1 (fr) 2012-02-06 2012-02-06 Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
EP13712915.1A EP2812449B1 (fr) 2012-02-06 2013-02-06 Utilisation de l'expression mir-199a-5p, cibles et/ou inhibiteurs de celle-ci pour le diagnostic, le pronostic et le traitement de troubles fibroproliférateurs
JP2014556174A JP6193269B2 (ja) 2012-02-06 2013-02-06 ｍｉＲ−１９９ａ−５ｐ、その標的及び／又は阻害剤の、線維増殖障害の診断、予後予測及び治療のための使用
US14/376,569 US20150045247A1 (en) 2012-02-06 2013-02-06 USE OF miR-199a-5p, TARGETS AND/OR INHIBITORS THEREOF FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS
ES13712915.1T ES2642188T3 (es) 2012-02-06 2013-02-06 Uso de miR-199a-5p, dianas y/o inhibidores del mismo para el diagnóstico, pronóstico y tratamiento de trastornos fibroproliferativos
CA2862275A CA2862275C (fr) 2012-02-06 2013-02-06 Utilisation de l'expression mir-199a-5p, cibles et/ou inhibiteurs de celle-ci pour le diagnostic, le pronostic et le traitement de troubles fibroproliferateurs
DK13712915.1T DK2812449T3 (en) 2012-02-06 2013-02-06 USE OF miR-199a-5p, TARGETS AND / OR INHIBITORS THEREOF FOR DIAGNOSTICS, PROGNOSTICS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS
PCT/IB2013/050989 WO2013118066A1 (fr) 2012-02-06 2013-02-06 Utilisation de l'expression mir-199a-5p, cibles et/ou inhibiteurs de celle-ci pour le diagnostic, le pronostic et le traitement de troubles fibroproliférateurs
US15/397,351 US10647984B2 (en) 2012-02-06 2017-01-03 Use of miR-199a-5p, targets and/or inhibitors thereof for the diagnosis, prognosis and treatment of fibroproliferative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1251089A FR2986538B1 (fr) 2012-02-06 2012-02-06 Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives

Publications (2)

Publication Number Publication Date
FR2986538A1 FR2986538A1 (fr) 2013-08-09
FR2986538B1 true FR2986538B1 (fr) 2016-03-11

Family

ID=48014123

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1251089A Active FR2986538B1 (fr) 2012-02-06 2012-02-06 Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives

Country Status (8)

Country Link
US (2) US20150045247A1 (fr)
EP (1) EP2812449B1 (fr)
JP (1) JP6193269B2 (fr)
CA (1) CA2862275C (fr)
DK (1) DK2812449T3 (fr)
ES (1) ES2642188T3 (fr)
FR (1) FR2986538B1 (fr)
WO (1) WO2013118066A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986538B1 (fr) 2012-02-06 2016-03-11 Centre Nat Rech Scient Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
WO2017082943A1 (fr) * 2016-01-29 2017-05-18 The Government Of The United States, As Represented By The Secretary Of The Army Articles servant à diagnostiquer une fibrose hépatique
US11371097B2 (en) 2015-01-30 2022-06-28 The Government Of The United States, As Represented By The Secretary Of The Army Articles for diagnosis of liver fibrosis
EP3184646B1 (fr) * 2015-12-22 2019-04-17 Siemens Aktiengesellschaft Signatures specifiques dans alzheimer par profil mirna multicentique
CN106924757B (zh) * 2015-12-31 2020-07-24 中国科学院遗传与发育生物学研究所 miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用
US11097134B2 (en) * 2019-05-16 2021-08-24 Academia Sinica Caveolin-1 antibody for use in treating brain inflammation and injury and improving functional recovery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
EP2990487A1 (fr) * 2008-05-08 2016-03-02 Asuragen, INC. Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
WO2010039502A2 (fr) * 2008-09-23 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microarn afférents à la fibrose pulmonaire idiopathique
WO2011017697A1 (fr) * 2009-08-07 2011-02-10 New York University Compositions et méthodes pour traiter des troubles inflammatoires
EP2783016A1 (fr) * 2011-11-22 2014-10-01 Intermune, Inc. Procédés de diagnostic et de traitement de la fibrose pulmonaire idiopathique
FR2986538B1 (fr) 2012-02-06 2016-03-11 Centre Nat Rech Scient Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives

Also Published As

Publication number Publication date
US10647984B2 (en) 2020-05-12
CA2862275C (fr) 2022-12-06
DK2812449T3 (en) 2017-10-09
ES2642188T3 (es) 2017-11-15
JP2015513526A (ja) 2015-05-14
FR2986538A1 (fr) 2013-08-09
EP2812449B1 (fr) 2017-07-12
JP6193269B2 (ja) 2017-09-06
CA2862275A1 (fr) 2013-08-15
US20150045247A1 (en) 2015-02-12
EP2812449A1 (fr) 2014-12-17
WO2013118066A1 (fr) 2013-08-15
US20170183658A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
HRP20190116T1 (hr) Slit-robo signaliziranje, namijenjeno dijagnosticiranju i liječenju bubrežne bolesti
EP2971127A4 (fr) Procédés de diagnostic et de traitement de maladie intestinale inflammatoire
HUE043563T2 (hu) Biomarker és eljárások alzheimer-kór korai diagnosztizálására
FR2986538B1 (fr) Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
FR2948687B1 (fr) Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
EP2723866A4 (fr) Procédés de pronostic et/ou de diagnostic d'une maladie neurodégénérative, procédés d'identification de composés candidats et composés pour le traitement d'une maladie neurodégénérative
HK1221898A1 (zh) 腸易激綜合徵和炎性腸病的診斷和治療
EP2888370A4 (fr) Méthodes diagnostiques, pronostiques et méthodes de traitement
EA201792669A1 (ru) Igfbp3 и его применение
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3204008A4 (fr) Utilisation de biomarqueurs permettant de prédire la sensibilité clinique pour le traitement du cancer
FR2977798B1 (fr) Utilisation de composes oligosaccharidiques pour la prevention et le traitement des cicatrices pathologiques
HK1223129A1 (zh) 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用
FR2997837B1 (fr) Dispositif d'osteosynthese pour le traitement des fractures du col de femur.
FR3000895B1 (fr) Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
FR2984360B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du colon
FR2984361B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du testicule
FR2996004B1 (fr) Procede pour le diagnostic de dystrophies musculaires
FR2984362B1 (fr) Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
FR2993461B1 (fr) Utilisation de composes modifiant l'epigenome pour le traitement des maladies genetiques musculaires liees a une anomalie de conformation proteique
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
FR2984359B1 (fr) Procede pour le diagnostic ou le pronostic, in vitro, du cancer de la prostate
FR2987047B1 (fr) Utilisations des derives de carbazolophenones pour le traitement du cancer.
FR2992863B1 (fr) Composition pharmaceutique pour le traitement du cancer

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13